top of page

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression

Tetra Pharm Technologies has reached a significant in developing its compound for appetite suppression, TPT0701, following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS).

TPT0701 offers a novel approach to appetite suppression, aiming to provide individuals with a safe and effective means to manage their cravings and achieve their wellness goals. By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

ECS modulation has long been recognised as a promising avenue for appetite regulation. Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain. TPT0701 was originally designed in 2022 for obese patients suffering from schizophrenia but will now move into the development stage as appetite suppressing medication for general weight loss.

"With our new, proprietary platform technology as our secret weapon to unlock the endless possibilities of the endocannabinoid system, we are now ready to finalize TPT0701 for pre-clinical testing in 2024,” said Dr Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies. "Compounds, such as TPT0701, display physicochemical properties that render them difficult to formulate by means of conventional approaches. Our enabling platform technology, now with an IP application supporting it, can accommodate exactly these types of molecules and will help overcome otherwise hampering drug delivery challenges such as poor absorption and ultimately low bioavailability. Indeed, a drug is only as good as its delivery system, and with a check mark secured on both the formulation technology and the pharmacological mode of action established in early drug discovery, we are confident in the ongoing success of TPT0701 as it progresses through development.”


bottom of page